Scholar Rock (SRRK) Stock Price, News & Analysis

Company Overview

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA). In addition to its SMA candidate, Scholar Rock is advancing therapeutic candidates that inhibit other members of the transforming growth factor-beta (TGF-β) superfamily. These programs address indications such as fibrotic diseases, immuno-oncology and rare genetic bone disorders, with several assets in preclinical or early clinical development.

Scholar Rock’s proprietary platform combines structural biology, protein engineering and translational pharmacology to identify and optimize molecules that bind selectively to growth factor precursors or associated regulatory proteins. By focusing on the latency and activation mechanisms of signaling proteins, the company seeks to fine-tune growth factor activity, reduce off-target effects and expand the range of treatable conditions. Collaboration with academic institutions and strategic partnerships supports the advancement of its pipeline and fosters translational science.

Founded in 2013 and headquartered in Cambridge, Massachusetts, Scholar Rock is led by President and CEO Paul J. Rubin. The company conducts clinical trials and research collaborations in North America and engages with global regulators and investigators to advance its programs. Scholar Rock’s executive team and board include leaders with experience in biopharmaceutical development, clinical strategy and regulatory affairs, underscoring its commitment to delivering innovative therapies to patients with high-unmet-need conditions.

Key Stats

• Today's Range: $31.08 to $32.87
• 50-Day Range: $30.17 to $42.86
• 52-Week Range: $6.76 to $46.98
• Volume: 2.11 million shs
• Average Volume: 1.71 million shs
• Market Capitalization: $3.02 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $45.75
• Consensus Rating: Buy

Scholar Rock Stock Analysis - MarketRank™

Scholar Rock scored higher than 90% of companies evaluated by MarketBeat, and ranked 113th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Scholar Rock has received a consensus rating of Buy. The company's average rating score is 3.20, and is based on 8 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Scholar Rock has a consensus price target of $45.75, representing about 45.7% upside from its current price of $31.41.

Amount of Analyst Coverage

Scholar Rock has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Scholar Rock are expected to grow in the coming year, from ($2.42) to ($2.12) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Scholar Rock is -10.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scholar Rock is -10.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Scholar Rock has a P/B Ratio of 7.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

16.09% of the outstanding shares of Scholar Rock have been sold short.

Short Interest Ratio / Days to Cover

Scholar Rock has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Scholar Rock has recently increased by 4.03%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scholar Rock does not currently pay a dividend.

Dividend Growth

Scholar Rock does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.4 / 5
• Environmental Score: -1.09

Percentage of Shares Shorted

16.09% of the outstanding shares of Scholar Rock have been sold short.

Short Interest Ratio / Days to Cover

Scholar Rock has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.

Change versus previous month

Short interest in Scholar Rock has recently increased by 4.03%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.56

News Sentiment

Scholar Rock has a news sentiment score of 1.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 11 news articles for Scholar Rock this week, compared to 7 articles on an average week.

Search Interest

13 people have searched for SRRK on MarketBeat in the last 30 days. This is an increase of 44% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Scholar Rock to their MarketBeat watchlist in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Scholar Rock insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,299,310.00 in company stock.

Percentage Held by Insiders

13.30% of the stock of Scholar Rock is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

91.08% of the stock of Scholar Rock is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SRRK Stock Analysis - Frequently Asked Questions

How have SRRK shares performed this year?

Scholar Rock's stock was trading at $43.22 at the beginning of the year. Since then, SRRK shares have decreased by 27.3% and is now trading at $31.41.

How were Scholar Rock's earnings last quarter?

Scholar Rock Holding Corporation (NASDAQ:SRRK) posted its quarterly earnings results on Wednesday, August, 6th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.66) by $0.32.
Read the conference call transcript.

When did Scholar Rock IPO?

Scholar Rock (SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Scholar Rock's major shareholders?

Top institutional investors of Scholar Rock include Redmile Group LLC (4.09%), State Street Corp (3.20%), Bellevue Group AG (3.07%) and Eventide Asset Management LLC (3.03%). Insiders that own company stock include Public Equities LP Invus, Samsara Biocapital Gp, Llc, Srinivas Akkaraju, Akshay Vaishnaw, Jay T Backstrom, Junlin Ho, Caryn Parlavecchio, Mo Qatanani, Edward H Myles, Tracey Sacco, Jing L Marantz, Michael Gilman, Katie Peng, Jeffrey S Flier, Kristina Burow and Joshua Reed.
View institutional ownership trends.

How do I buy shares of Scholar Rock?

Shares of SRRK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Scholar Rock own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Scholar Rock investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Netflix (NFLX), Tesla (TSLA), First Solar (FSLR) and JPMorgan Chase & Co. (JPM).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/06/2025
• Next Earnings (Estimated): 11/11/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SRRK
• CIK: 1727196
• Web: www.scholarrock.com
• Phone: (857) 259-3860
• Fax: 866-493-4935
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Scholar Rock: $45.75
• High Price Target: $53.00
• Low Price Target: $31.00
• Potential Upside/Downside: +45.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.20
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$246.29 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -127.11%
• Return on Assets: -90.09%

Debt

• Debt-to-Equity Ratio: 0.21
• Current Ratio: 6.33
• Quick Ratio: 6.33

Sales & Book Value

• Annual Sales: $33.19 million
• Price / Sales: 90.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $3.94 per share
• Price / Book: 7.97

Miscellaneous

• Outstanding Shares: 96,130,000
• Free Float: 83,342,000
• Market Cap: $3.02 billion
• Optionable: Optionable
• Beta: 0.36